Real-time surveillance with ctDNA in stage III BRAF-positive melanoma
Автор: VJOncology
Загружено: 2024-12-06
Просмотров: 32
Описание:
Gabriele Roccuzzo, MD, University of Turin, Turin, Italy, shares results from a longitudinal study, which explored the predictive accuracy of circulating tumor DNA (ctDNA) for relapse risk in patients with stage III BRAF-positive cutaneous melanoma. The cohort consisted of 32 patients who received either immunotherapy or targeted therapy in adjuvant settings. A 12-month follow-up revealed that patients who expressed higher levels of ctDNA were correlated to a higher risk of relapse. This interview took place at The European Congress on Dermato-Oncology 2024 in Vienna, Austria.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
